<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862589</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1128</article-id><article-id pub-id-type="other">EPV0423</article-id><article-id pub-id-type="pii">S0924933824011283</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Tolerability of intranasal esketamine, a case series of 15 patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>&#x000c1;lvarez Correa</surname><given-names>I.</given-names></name><xref rid="aff2540" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Delgado Marmisa</surname><given-names>C.</given-names></name><xref rid="aff2540" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vizca&#x000ed;no Herrezuelo</surname><given-names>H. J.</given-names></name><xref rid="aff2540" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eg&#x000fc;en Recuero</surname><given-names>L.</given-names></name><xref rid="aff2541" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garrido Dobrito</surname><given-names>E.</given-names></name><xref rid="aff2541" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>T&#x000e9;llez de Cepeda</surname><given-names>L. D.</given-names></name><xref rid="aff2542" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gayubo Moreo</surname><given-names>L.</given-names></name><xref rid="aff2543" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor0984" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sanz-Ar&#x000e1;nguez &#x000c1;vila</surname><given-names>B.</given-names></name><xref rid="aff2543" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Caballero Mart&#x000ed;nez</surname><given-names>L.</given-names></name><xref rid="aff2544" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>de Arce Cord&#x000f3;n</surname><given-names>R.</given-names></name><xref rid="aff2545" ref-type="aff">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="aff2540">
<sup>1</sup>
<institution>M.I.R. Psiquiatr&#x000ed;a</institution>
</aff><aff id="aff2541">
<sup>2</sup>
<institution>Enfermer&#x000ed;a Psiquiatr&#x000ed;a</institution>
</aff><aff id="aff2542">
<sup>3</sup>
<institution>F.E.A Farmacolog&#x000ed;a Cl&#x000ed;nica</institution>
</aff><aff id="aff2543">
<sup>4</sup>
<institution>F.E.A Psiquiatr&#x000ed;a</institution>
</aff><aff id="aff2544">
<sup>5</sup>
<institution>Jefe de Secci&#x000f3;n Psiquiatr&#x000ed;a</institution>
</aff><aff id="aff2545"><sup>6</sup><institution>Jefa de Servicio Psiquiatr&#x000ed;a, Hospital Universitario Puerta de Hierro Majadahonda</institution>, <city>Madrid</city>, <country>Spain</country></aff><author-notes><corresp id="cor0984"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1103">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S543</fpage><lpage>S543</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824011283a.pdf"/><abstract><sec id="sec5916"><title>Introduction</title><p>Intranasal esketamine has recently been approved for the treatment of treatment-resistant depression in adults, with different studies showing its efficacy and tolerability. However, the real-world tolerability of this treatment is still unclear.</p></sec><sec id="sec5917"><title>Objectives</title><p>Evaluate the tolerability of intranasal esketamine in a case series of 15 patients.</p></sec><sec id="sec5918"><title>Methods</title><p>Our case series includes 15 patients, who received treatment with intranasal esketamine during 2022-2023. In order to evaluate the tolerability of intranasal esketamine, patients were asked to complete the TSQM and a side effect questionnaire on different moments of the treatment (one week, six weeks and six months after the beginning of the treatment).</p></sec><sec id="sec5919"><title>Results</title><p>The most common adverse effects were dissociation, dizziness, and somnolence, which resolved within the hours following the administration. All of them were mild or moderate in severity, having a minor impact on the patient, so none of the patients discontinued the treatment due to adverse effects. Other adverse effects noticed were: transitory increment of blood pressure in several patients, and worsening of obsessions in a patient with previous obsessive-compulsive symptoms.</p></sec><sec id="sec5920"><title>Conclusions</title><p>
Our data suggests that intranasal esketamine is well tolerated, with transient and mild adverse effects. In all cases the risk-benefit ratio must be evaluated, but until more studies are done, it seems to be a safe treatment for treatment-resistant depression.</p></sec><sec id="sec5921"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>